Juan Miguel Mendoza
Known title: DirectorCIK: 0001738284
Juan Miguel Mendoza's purchase track record
How the stock did after each of Juan Miguel Mendoza's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
11
of 11 since March 8, 2024
Stock higher 6 months later
55%
3 months: 73%
Median 6-month return
+1.3%
3 months: +16.3%
Beat the S&P 500
36%
median -10.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/5/2025 | HLF | $24K | +35.6% | +62.4% | +15.4% |
| 5/22/2025 | HLF | $34K | +31.9% | +38.5% | +11.9% |
| 5/2/2025 | HLF | $34K | +24.9% | +9.3% | +20.3% |
| 2/27/2025 | HLF | $61K | -4.1% | +11.0% | +10.9% |
| 11/4/2024 | HLF | $61K | -35.6% | -11.5% | -1.1% |
| 9/9/2024 | HLF | $71K | +16.3% | +30.6% | +2.6% |
| 8/26/2024 | HLF | $87K | +0.5% | +1.3% | +6.5% |
| 8/13/2024 | HLF | $54K | +6.9% | -31.7% | +11.7% |
| 5/6/2024 | HLF | $236K | -1.5% | -15.3% | +10.3% |
| 3/26/2024 | HLF | $151K | +16.8% | -18.2% | +10.2% |
| 3/8/2024 | HLF | $100K | +22.1% | -18.1% | +5.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HLF | ▲ Buy | Grant | 11,879 | $0 | 5/8/2026 | View on chart |
| HLF | ▲ Buy | Open Market | 3,143 | $24K | 6/5/2025 | View on chart |
| HLF | ▲ Buy | Open Market | 5,000 | $34K | 5/22/2025 | View on chart |
| HLF | ▲ Buy | Open Market | 5,000 | $34K | 5/2/2025 | View on chart |
| HLF | ▲ Buy | Grant | 21,857 | $0 | 5/2/2025 | View on chart |
| HLF | ▲ Buy | Open Market | 2,500 | $20K | 3/4/2025 | View on chart |
| HLF | ▲ Buy | Open Market | 5,000 | $41K | 2/27/2025 | View on chart |
| HLF | ▲ Buy | Open Market | 2,500 | $21K | 11/8/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 2,500 | $20K | 11/5/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 2,500 | $20K | 11/4/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 10,000 | $71K | 9/9/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 10,000 | $87K | 8/26/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 6,721 | $54K | 8/13/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 7,000 | $75K | 5/10/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 5,500 | $58K | 5/9/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 2,500 | $25K | 5/8/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 5,000 | $49K | 5/7/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 3,000 | $29K | 5/6/2024 | View on chart |
| HLF | ▲ Buy | Grant | 15,657 | $0 | 5/3/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 16,079 | $151K | 3/26/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 4,421 | $40K | 3/11/2024 | View on chart |
| HLF | ▲ Buy | Open Market | 6,500 | $59K | 3/8/2024 | View on chart |
| HLF | ▲ Buy | Grant | 11,029 | $0 | 5/4/2023 | View on chart |
| HLF | ▲ Buy | Grant | 5,387 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
HLF Featured in Mixed Stock Lists Amid High RSI
Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.
HLF Featured in Mixed Stock Lists Amid High RSI. Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.